Premium
Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter
Author(s) -
Ryder R. E. J.
Publication year - 2015
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.12703
Subject(s) - pioglitazone , medicine , observational study , meta analysis , bladder cancer , adverse effect , randomized controlled trial , clinical trial , cancer , oncology , intensive care medicine , diabetes mellitus , type 2 diabetes , endocrinology